Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat + Vincristine, Irinotecan, and Temozolomide in Relapsed/Refractory Solid Tumors and CNS Malignancies
NCT04308330Phase 1Recruiting
- Sponsor
- New York Medical College
- Start
- Mar 2017
- Primary completion
- Dec 2026
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vorinostat in solid tumor, central nervous system malignancy, Ewing sarcoma and 5 more, sponsored by New York Medical College. Primary endpoint: Maximum Tolerated Dose at 1 year. Started Mar 2017; status: recruiting.
02
Drugs
vorinostat
03
Conditions
solid tumorcentral nervous system malignancyEwing sarcomarhabdomyosarcoma (RMS)Wilms' tumor
Beyond the preview
Go deeper on NCT04308330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04308330.